Section
This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise fo
A phase 2 randomized trial in CKD patients shows lubiprostone preserves renal function by modulating gut microbiota polyamine pathways and improving mitochondrial health, independent of uremic toxin levels, offering a novel therapeutic aven
Flexovital, a nitric oxide-enhancing supplement, effectively attenuates metabolic, cardiovascular, and renal dysfunctions in a mouse model of cardiovascular-kidney-metabolic syndrome induced by unilateral nephrectomy and Western diet.
This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone’s efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing futur
The ALCHEMIST trial reveals spironolactone does not improve cardiovascular outcomes in high-risk chronic haemodialysis patients, aligning with a meta-analysis that challenges the benefit of mineralocorticoid receptor antagonists in this pop
Uremia, the deadly end-stage of kidney disease, is increasingly diagnosed in younger adults. Early detection and lifestyle changes can prevent progression. This article explores risk factors, symptoms, diagnosis, treatment options, and prev
A 25-year-old woman with recurrent urinary tract infections was diagnosed with unilateral renal agenesis, highlighting the importance of imaging in persistent urinary symptoms.
Epaminurad significantly lowers serum urate levels in gout patients with excellent safety, offering a promising alternative to existing therapies. This randomized controlled trial identifies optimal dosing and confirms tolerability over 12
Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-
A large real-world study shows that SGLT2 inhibitors significantly slow kidney function decline and improve albuminuria compared with other glucose-lowering drugs in type 2 diabetes patients with chronic kidney disease.
Cisplatin chemotherapy is associated with predictable kidney function decline, with pre-treatment eGFR effectively forecasting chronic kidney disease risk post-treatment. Simple models outperform complex approaches, offering practical clini
Complementary and alternative medicine (CAM) use is prevalent in chronic kidney disease (CKD), with 43% of patients globally employing CAM modalities. Nutritional supplements, mind-body practices, and traditional medicines are widely used,
Perioperative nitric oxide administration in CKD patients undergoing cardiac surgery significantly reduces acute kidney injury incidence and preserves renal function, while demonstrating safety and additional benefits against postoperative
This phase 3 trial demonstrates that anrikefon significantly reduces pruritus intensity and improves quality of life in patients undergoing haemodialysis with moderate to severe chronic kidney disease-associated pruritus, with a favorable s
Prasugrel demonstrates a more rapid and significant inhibition of platelet aggregation than clopidogrel in patients with stable coronary artery disease and impaired renal function, particularly within the first week of therapy.
Kidney-transplant recipients on long-term kidney replacement therapy demonstrate significant reductions in COVID-19-related hospitalizations and mortality following three or more vaccine doses, supporting booster vaccinations in this vulner
A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.
The NUDGE-CKD trial found that electronic letter-based nudges to patients with chronic kidney disease and their general practitioners did not significantly improve initiation of guideline-recommended medications over usual care.
The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.
A multicenter randomized trial demonstrates that delayed remote ischemic preconditioning 24 hours prior to coronary angiography or PCI significantly lowers the incidence of contrast-associated acute kidney injury in high-risk patients.
